The USPTO issued US Patent 12589114B2 to the Board of Trustees of the Leland Stanford Junior University covering GABRR1-targeted methods for regulating hematopoiesis. The patent discloses that GABRR1 expressed on hematopoietic stem cells and megakaryocyte progenitors can be manipulated using agonists to promote platelet production or antagonists to inhibit platelet generation. Seven claims protect compositions and methods relating to GABAA receptor subunit GABRR1 manipulation for therapeutic applications.

For companies developing cell therapy products, blood disorders treatments, or platelet regeneration therapies, this patent may affect freedom-to-operate considerations. Researchers should review the patent claims before conducting commercial research involving GABA receptor modulation in hematopoiesis. No immediate compliance actions are required, but R&D teams should assess potential licensing needs if working in this technological space.